A fish oil (FO)-containing intravenous lipid emulsion (ILE; FO ILE) has been approved for use in the United States; however, similar formulations have been used throughout Europe and China in intensive care units since the 1990s. This literature review evaluates the evidence regarding the effectiveness of FO ILE on clinical outcomes in the critically ill surgical patient population. The review of available evidence demonstrates that ILEs containing FO lower triglyceride concentrations, inflammatory markers, and liver function enzymes, and improve morbidity and mortality outcomes in critically ill surgical patients. (Nutr Clin Pract.
Introduction
Until 2016, the only intravenous lipid emulsions (ILEs) approved for use in the United States were composed of 100% soybean oil (SO). However, alternative ILE blends containing SO, olive oil (OO), fish oil (FO), and/or mediumchain triglycerides (MCTs) have been used since the 1990s throughout Europe and China for adult and pediatric patients requiring parenteral nutrition (PN). In 2016, the U.S. Federal Drug Administration (FDA) approved the first alternative composite mixed-oil ILE for use in adult patients, which is a 4-oil lipid emulsion composed of SO (30%), MCTs (30%), OO (25%), and FO (15%). 1 The use of 100% SO ILE in critically ill patients is controversial among clinicians due to the proinflammatory nature of the long-chain triglycerides (LCTs) that make up SO. [2] [3] [4] The Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient 5 recommend withholding or limiting SO based ILE during the first week that patients require PN, a recommendation largely based on a study showing increased morbidity in trauma patients who were given SO-based ILE. 6 However, recent studies showing improved outcomes in patients with sepsis who receive ω-3 FO supplements 7, 8 indicate that alternative ILE products, specifically fish oilcontaining intravenous lipid emulsion (FO ILE) products, could improve patient care for surgical patients who require PN. The SCCM and ASPEN guidelines were published before the approval of the new composite mixed-oil ILE in the United States; however, based on available studies at that time, the authors did suggest that alternative ILEs could provide beneficial outcomes compared with SO-based ILE. 5 Furthermore, the authors suggest that the use of alternative ILE should be considered in critically ill patients when approved for use in the United States. 5 Although this alternative lipid emulsion has been approved in the United States since 2016, questions remain about the indications for its use, specifically whether the use of FO ILE instead of the traditional 100% SO-based ILE improves clinical outcomes (morbidity and mortality) and biochemical outcomes (serum triglycerides, inflammatory markers, liver function) in critically ill surgical patients requiring PN during their intensive care unit (ICU) stay. The aim of this review is to evaluate the evidence of FO ILE to improve outcomes in critically ill surgical patients who require PN during their ICU stay.
Search Strategy
Literature searches were completed in the PubMed, CIN-HAL, and EMBASE databases, using the following search terms: parenteral nutrition, alternative lipids, fish oil, inflammation, critical care, surgical, length of stay, and intensive care. Studies were excluded if they were published before 2007, did not include specific dosage information or reviewed enteral FO administration, or were written in languages other than English. Pediatric studies were excluded as part of the literature review. Reference lists from original research articles and systematic reviews were searched for any relevant articles not found during the database searches. An overview of each original research article reviewed is included in Table 1 .
Literature Review

Serum Triglycerides
It is not uncommon for patients receiving PN to experience increases in serum triglyceride concentrations. [9] [10] [11] Hypertriglyceridemia is often correlated with hepatic steatosis, which can contribute to liver damage. 12 Liver damage can progress to liver failure, which significantly increases morbidity and could lead to mortality. Previous nutrition support guidelines suggested ILE be removed from PN prescriptions when serum triglycerides are >250 mg/dL if the patient is receiving intermittent administration of ILE, or >400 mg/dL if the patient is receiving ILE continuously. [13] [14] [15] However, the most recent SCCM/ASPEN guidelines do not mention serum triglyceride limits for patients receiving ILE. 5 A randomized control trial (RCT) of gastrointestinal surgery patients receiving PN postoperatively for 6 days (n = 35) found that although both the control (250 mL 50:50 MCT:LCT ILE) and intervention (250 mL of Smoflipid, a 30:30:25:15 SO:MCT:OO:FO blend) groups had significant increases in serum triglycerides by day 6 (P < .001 and P = .012, respectively), the intervention group had significantly lower incremental increases than the control group (change in the control group from day 1 to day 6 was 62.9 ± 38.0 mg/dL, and change in the intervention group was 26.9 ± 46.4 mg/dL; P = .029). 16 Interestingly, control group patients had a statistically significant increase in serum triglycerides even by day 2 (P < .001), whereas the intervention group did not. 16 Similarly, a double-blind RCT of 30 surgical ICU patients found that patients receiving a 40:40:20 ratio of MCT:LCT:FO had significantly lower serum triglyceride levels on day 4 (P = .045) compared with patients receiving 50:50 MCT:LCT ILE. 17 However, the authors found no significant difference by postoperative day (POD) 7, which could be because of the small sample size of the study. 17 Despite this, their findings add to the evidence that FO ILEs have been shown to be protective to rapid increases in serum triglycerides. 17 In a double-blind RCT of 24 postoperative patients with abdominal aorta aneurysm repair, Berger et al 18 found no statistically significant differences in serum triglycerides between those patients receiving FO-containing PN (0.15 g/kg body weight/d of 40:50:10 LCT:MCT:FO) and the control group (0.15 g/kg body weight/d of 50:50 LCT:MCT). In post hoc analysis, both groups had statistically significant increases in serum triglycerides (P < .01); however, levels remained <250 mg/dL (2.0 mmol/L, 177 mg/dL) in both groups. 18 Their data did show higher levels of eicosapentaenoic acid (EPA; P < .0001) and docosahexaenoic acid (DHA; P < .001) in the FO group when compared with the control group, which is expected given the addition of FO to the ILE. 18 Throughout the course of the studies, all of the serum triglyceride levels in these studies remained lower than thresholds commonly used for ILE removal as outlined earlier. [13] [14] [15] [19] [20] [21] Table 2 displays results from all studies discussed for cross reference. Overall, studies suggest that FO ILE may be protective against rapid increases in serum triglycerides. [16] [17] [18] All comparison ILE from these studies were 50:50 ratios of LCT:MCT, which contained higher or equivalent amounts of MCTs than the FO ILE used for interventions. MCTs are more rapidly metabolized than other fatty acids, which may be responsible for the shift in statistically significant differences over time. 22, 23 None of the studies reviewed compared 100% LCT ILE with an ILE blend containing FO, and studies reviewed had variable amounts of MCTs in both the intervention and control groups, so it is difficult to determine the influence of the FO by itself on these outcomes. [16] [17] [18] However, given that the historical standard of care contains only SO lipid, the impact of changing to a product that contains both MCTs and FO could be much greater than reflected in the reviewed studies.
Inflammatory Markers
Surgical critical care patients experience high levels of inflammation. 24 Studies reviewed found that patients who received FO ILE had lower proinflammatory markers. 7, 17, [25] [26] [27] [28] A double-blind RCT of 78 patients with severe sepsis and acute gastrointestinal injury grade III found lower cluster of differentiation 3 (CD3) T lymphocytes (mean difference −8.21; 95% CI: −15.11 Notably, although the intervention group in this study received more calories from fat than the control group, both groups received the same amount of overall calories (20 kcal/kg for the first 7 days and 30 kcal/kg thereafter). 7 Unfortunately, the authors did not discuss the amino acid and dextrose dosing, which could affect inflammatory responses. 7 Although not all subjects in this study were surgical patients, all of the subjects did have severe sepsis, which is an inflammatory state. 7, 29 There was no significant difference in the number of surgical patients included in the control and intervention groups (P = 1.00). 7 Han et al 17 investigated the relationship between parenteral FO and immune modulation in their study of 30 surgical ICU patients, and they found lower levels of interleukin (IL)-1 (P = .00001), IL-6 (P = .0185), IL-8 (P = .0001), interferon γ (INF-γ ) (P = .0037), and tumor necrosis factor-α (TNF-α; P = .0230) in patients receiving a 40:40:20 ratio of MCT:LCT:FO compared with patients receiving a 50:50 ratio of MCT:LCT. A meta-analysis of postoperative patients with colorectal cancer also showed that patients receiving FO-containing PN had lower levels of TNF-α (P = .01) and IL-6 (P = .02). 26 Similarly, a large metaanalyses of 19 RCTs of perioperative patients (n = 1167) by Bae et al 27 found that patients who received FO-containing PN had a reduction in TNF-α, whereas those without FO in their PN did not (P = .0009). In addition, Liang et al 25 found patients who received a 5:1 ratio of LCT:FO had lower IL-6 levels by POD 8 (P = .039) and higher CD4 + /CD8 + levels (P = .035) than the control group who received 100% LCTs from SO.
In a large, multicenter, randomized, prospective study of 256 surgical patients with both acute and chronic medical conditions, researchers found that patients receiving FO ILE (50:40:10 ratio of MCT:LCT:FO) had significantly lower leukotriene B 5 (P = .0012) and a better EPA:arachidonic acid ratio (P = .0023) compared with the control group, who received the traditional standard of care in the United States (100% LCTs from SO). 28 Both groups received 0.7 g lipid/kg for the first 2 PODs and increased to 1.4 g lipid/kg for PODs 3-5. 28 The same study also found patients in the FO group had higher α-tocopherol levels (P < .0001), likely because the FO-containing lipids contain α-tocopherol to protect the FO from peroxidation. 28 Although α-tocopherol in itself is not an inflammatory marker, it has been shown to decrease inflammation in both in vitro and in vivo studies and lower levels of IL-6, IL-8, and TNF-α. 30 A long-term PN study showed that despite the addition of α-tocopherol to a mixed-oil composite ILE, α-tocopherol levels stabilize over time and no symptoms of toxicity or elevated serum levels were found. 31 However, this increase in α-tocopherol intake would require closer monitoring for adverse effects, which include impaired neutrophil function, skeletal muscle lesions with ceroid deposits in smooth muscle, and abrogated granulocytopenic response to antigen. 32 A meta-analysis also found lower proinflammatory markers in patients who received FO ILE. 33 The FO ILE group had lower TNF-α (P = .02) and IL-6 levels (P < .0001) than the group without FO in their ILE. 33 In addition, the FO ILE group had higher CD4 + (P = .03) and CD4 + /CD8 + (P = .008) levels. 33 Two studies in this review did not find statistically significant differences in inflammatory markers. 16, 34 The first was a randomized study of patients undergoing gastrointestinal surgery that compared a 30:30:25:15 ratio of SO:MCT:OO:FO with a 50:50 ratio of MCT:LCT and found no significant differences over time in IL-6, IL-10, or TNF-α (P = .813, P = .845, and P = .551, respectively). 16 The second study was a double-blind randomized study of postoperative patients with gastrointestinal tumor that compared a 30:30:25:15 ratio of SO:MCT:OO:FO with a 50:50 ratio of MCT:LCT. 34 As in the first study, the authors found no difference in IL-1β, IL-6, TNF-α, or C-reactive protein (P = .866, P = .214, P = .164, and P = .123, respectively), and the study included 40 patients receiving PN for 5 days. 34 Although 2 studies did not find significant differences in inflammatory markers, 16, 34 the majority of studies 7, 17, [25] [26] [27] [28] 33 did find statistically significant differences. The circulation of these inflammatory markers promotes the catabolism of skeletal muscle and fat. 32 The findings of these studies show that FO ILE can significantly lower the circulation of inflammatory markers of patients in highly inflamed states when compared with patients who did not receive FO ILE.
Liver Function
Patients receiving PN are at higher risk for hepatobiliary complications including steatosis, cholestasis, and gallbladder sludge or stones; however, the cause remains unknown. 35 One proposed cause is the increase in phytosterol circulation in the blood after the introduction of SO-based ILE. 35 Normally, phytosterols are poorly absorbed in the intestines, and blood concentration of these phytosterols is therefore low. 35 In fact, high levels of phytosterols in blood circulation have been associated with liver toxicity. 35 Thus, in theory, ILE blends that contain lower amounts of lipid from plants, which reduce the amount of phytosterols delivered, should decrease the risk for hepatobiliary complications.
A 4-week, double-blind, multicenter RCT of 73 patients with intestinal failure comparing patients receiving a 100% SO-based ILE with patients receiving a 30:30:25:15 ratio of SO:MCT:OO:FO found that patients receiving the SO:MCT:OO:FO blend had significantly lower alanine transaminase, aspartate transaminase, and total bilirubin (P < .05, P = .03, and P = .04, respectively). 31 Specifically, alanine transaminase levels decreased an average of 7.8 U/L in the intervention group, whereas the control group's level increased an average of 3.6 U/L. 31 Aspartate transaminase decreased an average of 5.5 U/L in the intervention group, whereas the control group's level increased an average of 0.6 U/L. 31 In addition, on average, the total bilirubin levels in the intervention group decreased by 0.03 mg/dL and the control group's total bilirubin levels increased by 0.11 mg/dL. 31 Han et al's 17 study found that 50% of patients in the non-FO group had elevated liver function tests, compared with only 33.3% of the FO receiving group; however, this difference was not statistically significant. Another study found that patients receiving FO in their ILE had higher increases in pre-serum albumin level (P = .0049), which could reflect both improved liver function and decreased inflammation because there is an inverse correlation between inflammation and pre-serum albumin/serum albumin levels. 18 A meta-analysis of 21 RCTs showed decreases in liver function enzymes. 33 The alanine aminotransferase of patients who received FO ILE was, on average, 6.35 U/L lower (P = .02) than those who did not receive FO in their PN. 33 In addition, on average, the γ -glutamyltransferase was 11.01 U/L lower (P = .03) and the total bilirubin was 0.12 mg/dL lower (P = .009) in the FO ILE group. 33 Overall, the evidence suggests that FO-containing PN may help improve liver function tests in ICU patients.
Morbidity, Mortality, and Length of Stay
Although the improvement in laboratory markers reviewed in the literature is important, 7, [16] [17] [18] [25] [26] [27] [28] 31 the question remains whether these improvements translate into measurable clinical outcomes, which would improve patient outcomes and hospitalization costs. Chen et al 7 reported a significant decrease in 60-day mortality in their study of patients with severe sepsis and acute gastrointestinal injury grade III receiving FO ILE compared with subjects receiving 100% SO-based ILE (26.8% for the FO ILE group compared with 48.6% for the SO group; odds ratio, 0.387; P = .046). Further subgroup analysis demonstrated that patients with abdominal infections had both decreased 60-and 28-day mortality (P = .01 and P = .02, respectively) when patients received 10 g of FO with their 50 g of SO compared with the 50 g of SO alone. 7 Although only a portion of this population was surgical patients, this study showed lower inflammatory markers with use of FO ILE in a population who experienced high levels of systemic inflammation, similar to the high inflammatory state of patients in a surgical ICU with a resultant decreased mortality rate. 7 The Bae et al 27 study described previously also found that patients receiving FO ILE had significantly reduced infectious morbidity (odds ratio, 0.44; P < .0001). More specifically, the authors noted that the effect was greatest in patients receiving FO-containing PN compared with those receiving SO-based ILE only. 27 A meta-analysis of 21 RCTs found no significant difference in mortality between patients receiving FO ILE and patients receiving ILE without FO. 33 However, authors did find that the FO ILE group experienced significantly fewer infection complications (P = .003; odds ratio, 0.53 [95% CI: 0.35-0.81]). 33 A systematic review by Wei et al 36 of RCTs studying postoperative elective surgery patients did not find any statistically significant difference in mortality between groups (P = .46). However, this analysis excluded studies of patients with critical medical illness, tumor chemotherapy, and transplants, so the patient sample was expected to have a low mortality risk at baseline. 36 This study did find that patients receiving FO-containing PN had a 51% decrease in risk for infectious morbidity compared with patients receiving PN without FO (risk ratio = 0.49; P = .03), which could be interpreted as an outcome related to the decrease in inflammatory markers noted in the included studies reviewed earlier. 36 Researchers have also observed a trend toward decreased hospital and intensive care unit (ICU) length of stay (LOS) in patients receiving FO ILE. Berger et al 18 found that patients receiving FO ILE had an 11-day shorter ICU LOS. Although not statistically significant (P = .22), an 11-day shorter hospital stay provides meaningful benefits to patients' long-term outcomes. 18 Similarly, Liang et al 25 found a trend toward shorter postoperative hospital stays in patients who received FO ILE compared with those who did not (17.45 ± 4.80 vs 19.62 ± 5.59 days, respectively; P = .19). Interestingly, the study with the largest sample size (n = 256) did find a statistically significant difference in hospital LOS (P = .0061). 28 Specifically, those in the group receiving FO ILE had a hospital LOS of 17.2 days compared with 21.9 days in the 100% LCT ILE group. 28 Although the hospital LOS in this study was long, this could be expected given that these patients were very sick and had intensive surgical interventions and complications. 28 Although individually some reviewed studies showed trends toward, but not statistically significant, decreases in hospital LOS when ILE including FO was provided, 18, 25 some meta-analyses have found statistically significant differences. Xie et al's 26 meta-analysis of postoperative patients with colorectal cancer found that patients receiving FO had a significantly shorter postoperative LOS (mean difference −2.09 days; 95% CI: −3.71 to −0.48; P = .01). The Bae et al 27 meta-analysis also showed that patients receiving FO ILE had a 2.7-day shorter hospital LOS compared with patients receiving SO-based ILE (P < .00001). Similarly, Wei et al's 36 meta-analysis reported that patients receiving FO-containing PN had a statistically significant shorter hospital LOS (−1.61 days; P = .02) and ICU LOS (−2.07 days; P = .004). Li et al's 33 meta-analysis also found that patients who received FO ILE had a 2.14-day shorter hospital LOS (P < .00001; 95% CI: −3.02 to −1.27 days). Cumulatively, studies support that patients receiving FOcontaining PN have significant improvements in clinical outcomes, including morbidity, mortality, and hospital LOS. 7, 18, [25] [26] [27] [28] 33, 36 
Areas for Future Research
Historically the only available option for ILE in the United States was 100% SO-based ILE, but given the FDA approval of Smoflipid it is important to evaluate the benefits in consideration of changing products. As evidenced by the research reviewed, replacing some of the SO lipids with MCTs, OO, and FO could improve clinical outcomes. 7, [16] [17] [18] [25] [26] [27] [28] 31, 36 Further studies comparing 100% LCT ILE with composite mixed-oil ILEs containing FO are necessary to fully understand the impact of these blends on biochemical markers and patient outcomes in the United States. In addition, future research could look to determine the effects of usage of FO ILE on lean body mass losses and fat reserve losses, because critically ill patients frequently experience significant losses of both. 37 Future studies should also examine the impact of FO ILE on biochemical and clinical outcomes for nonsurgical and noncritical care hospitalized patient populations.
As per this review, FO ILE has been shown to have positive effects on serum triglycerides, 16, 17 immune modulation and inflammation, 7, 17, [25] [26] [27] [28] 33 liver function, 17, 18, 31, 33 morbidity, 27,36 mortality, 7 and hospital LOS. 18, [25] [26] [27] [28] 33, 36 Further research evaluating the relationship between increased use of FO ILE and antibiotic usage, infection rates, hospital LOS, and glucose control is needed to fully understand the clinical and financial impact of transitioning to FO ILE from 100% SO-based ILE.
Implications for Practice
Although new pharmaceutical products are oftentimes more expensive than the current standard of care products, it is important to synthesize the benefits of new products in relation to cost. Studies reviewed showed a trend toward decreased hospital and ICU LOS when using FO ILE. 18, 25, 28, 33 Financial data show that shortening LOS provides significant cost savings to health systems. 38, 39 These studies did not differentiate costs between those requiring PN and those receiving enteral nutrition or an oral diet; however, PN is commonly significantly more expensive than the latter. 40, 41 Less time in the ICU and the hospital may significantly decrease healthcare costs. It could also improve quality of life and long-term outcomes in patients because longer hospitalizations lead to general deconditioning and increase risk for infection. 42, 43 Given the findings of this literature review, clinicians in the United States may consider using alternative ILEcontaining FO for their surgical critical care patients, as appropriate, to help avoid complications of elevated serum triglycerides. [16] [17] [18] This literature review demonstrates that surgical patients who receive FO ILE may experience significantly lower levels of proinflammatory markers and liver function tests. 7, 17, 18, [25] [26] [27] [28] 31, 33 These patients may also benefit from a demonstrated trend toward lower morbidity, mortality, and hospital LOS. 7, 18, [25] [26] [27] [28] 33, 36 Clinicians should be mindful about providing adequate amounts of essential fatty acids when using alternative ILE blends to avoid essential fatty acid deficiency (EFAD). In addition, clinicians should consider closer monitoring for vitamin E toxicity symptoms, because α-tocopherol is commonly added to composite ILEs to protect lipids from peroxidation. Because there are multiple sources of lipid in ILE blends, clinicians should also be mindful of potential allergens.
Dosage and Other Considerations of Composite Mixed-Oil ILE
SO is the main source of the essential fatty acid linoleic acid (LA) in PN, which can be converted to the 2 other essential fatty acids: linolenic acid and arachidonic acid. Because the other oils in the emulsion may not provide LA, clinicians must ensure they provide adequate amounts of the composite mixed-oil ILE to prevent EFAD. The essential fatty acid status of patients in these studies was not discussed as part of this review, but due to the nature of composite mixedoil ILE, EFAD is an inherent risk. Generally, to prevent EFAD, 2%-4% of total calories should be from LA. 44 The composite mixed-oil ILE may also contain EPA, DHA, and arachidonic acid, which help prevent EFAD. Adult patients who do not receive adequate amounts of essential fatty acids can experience development of EFAD within 10 days. 44 Clinicians in the United States may be accustomed to trying to reduce the amount of lipids in their PN prescriptions. However, when these lipid reduction strategies are applied while using composite mixed-oil ILE, the patient is at higher risk for EFAD.
The most common contraindication for a composite mixed-oil ILE is allergies. For example, per the manufacturer prescribing information, known hypersensitivities to soy, OO, fish, and/or peanut are contraindications to Smoflipid use. 1 Even though there is no peanut oil in Smoflipid, peanut is included because in rare cases people with peanut allergies may also react to soy. Patients who have tolerated SO-based ILE or propofol (an SO lipidbased medication commonly used in the ICU) without complication should also tolerate composite mixed-oil ILE, which also contains SO.
Concerns have also been raised regarding risk for bleeding with use of parenteral FO emulsions. This is due to concerns regarding EPA and DHA decreasing platelet aggregation and activation. 45 Increased bleeding time has been reported; however, results from clinical trials have been inconsistent. 46 Studies have been unable to associate ω-3 fatty acid use with bleeding. [45] [46] [47] There have been case reports of fat overload syndrome with use of Smoflipid. 48, 49 Although the most recent ASPEN/SCCM Adult Guidelines and ASPEN/SCCM Pediatric Guidelines do not suggest or recommend lipid emulsion rate limits, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition and the European Society for Clinical Nutrition and Metabolism guidelines suggest lipids should be infused at 0.13-0.17 g/kg/h for infants and 0.08-0.13 g/kg/h for older children. 5, 50, 51 One case report was of a 2-year-old girl who received a rapid infusion of Smoflipid, 100 mL of Smoflipid over 30 minutes (3.6 g/kg/h), which is significantly higher than the recommended rate. 48 In another case, a 72-year-old man received 500 mL of Smoflipid over 4 hours and the patient experienced symptoms of fat overload syndrome 1 hour after infusion. 49 The manufacturer dosage information states that the maximum infusion rate for Smoflipid is not to exceed 0.5 mL/kg/h. 1 The adult patient's weight was not mentioned as part of the case study, so we are unable to determine whether the infusion exceeded this rate. 49 
Conclusions
This review of evidence demonstrates that the inclusion of FO in ILE provides statistically significant and clinically relevant improvements in biochemical measures and clinical outcomes in surgical patients who require PN. Patients experience slower increases in serum triglycerides, 16, 17 as well as an improvement in inflammation and liver function tests when FO is included as part of ILE. 7, 17, 18, [25] [26] [27] [28] 31, 33 Studies also demonstrate that these improvements in biochemical measures translate to improvements in clinical outcomes, including trends toward decreased morbidity, 7, 36 mortality, 27 and hospital LOS. 18, [25] [26] [27] [28] 33, 36 Given that FO ILEs have been shown to be safe and improve outcomes in numerous studies compared with the historically standard treatment in the United States (100% LCTs from SO) and compared with 50:50 blends of MCT:LCT ILE, surgical ICU clinicians in the United States can consider using FO ILE as an alternative standard of care.
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